Bharat Immunologicals (India) Buy Hold or Sell Recommendation

BIBCL -- India Stock  

INR 8.70  0.30  3.33%

Assuming 30 trading days horizon, and your above average risk tolerance our recommendation regarding Bharat Immunologicals Biologicals Corp Ltd is 'Strong Sell'. Macroaxis provides Bharat Immunologicals buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding BIBCL positions. The advice algorithm takes into account all of Bharat Immunologicals available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from BIBCL buy-and-hold prospective. Check also Bharat Immunologicals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool.

Time Horizon

Risk Tolerance

Symbol
Execute Advice
Sell Bharat ImmunologicalsBuy Bharat Immunologicals
Strong Sell

Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Not Available
For the selected time horizon Bharat Immunologicals Biologicals Corp Ltd has a mean deviation of 2.1, semi deviation of 0.0, standard deviation of 3.05, variance of 9.31, downside variance of 0.0 and semi variance of 0.0
We provide buy or sell advice to complement the prevailing expert consensus on Bharat Immunologicals. Our dynamic recommendation engine makes use of multi - dimensional algorithm to analyze the company potential to grow using all technical and fundamental data available at the time. To make sure Bharat Immunologicals is not overpriced, please confirm all Bharat Immunologicals fundamentals including its Operating Margin, Revenue, Debt to Equity, as well as the relationship between Price to Earning and Net Income .

Bharat Immunologicals Returns Distribution Density

Mean Return0.65Value At Risk6.42
Potential Upside4.57Standard Deviation3.05
 Return Density 
      Distribution 

Bharat Immunologicals Greeks

α
Alpha over DOW
=0.43
β
Beta against DOW=1.48
σ
Overall volatility
=3.17
Ir
Information ratio =0.27

Bharat Immunologicals Volatility Alert

Bharat Immunologicals Biologicals Corp Ltd exhibits very low volatility with skewness of 0.15 and kurtosis of 2.08. However, we advise investors to further study Bharat Immunologicals Biologicals Corp Ltd technical indicators to make sure all market info is available and is reliable.
    
 Better Than Average     
    
 Worse Than Average Compare Bharat Immunologicals to competition

Bharat Immunologicals Fundamental Vs Peers

FundamentalsBharat ImmunologicalsPeer Average
Return On Equity(10.18)% (15.17)%
Return On Asset(9.86)% (15.64)%
Profit Margin(12.30)% (5.50)%
Operating Margin(26.93)% (10.91)%
Current Valuation191.71M152.14B
Shares Outstanding43.18M1.43B
Price to Earning262.88X40.69X
Price to Book1.12X14.44X
Price to Sales1.10X17.81X
Revenue347.2M9.85B
Gross Profit75.53M21.75B
EBITDA(90.59M)1.41B
Net Income(42.69M)517.71M
Cash and Equivalents182.85M3.89B
Cash per Share4.25X5.17X
Debt to Equity3.80% 0.72%
Current Ratio1.79X3.30X
Book Value Per Share7.91X13.64X
Earnings Per Share(0.99)X2.30X
Number of Employees510.67K
Beta0.430.34
Market Capitalization380.85M29.78B

Bharat Immunologicals Alerts

Trading Alerts and Improvement Suggestions

Bharat Immunologicals generates negative expected return over the last 30 days
Bharat Immunologicals has high historical volatility and very poor performance
Bharat Immunologicals has high likelihood to experience some financial distress in the next 2 years
The company reported revenue of 347.2M. Net Loss for the year was (42.69M) with profit before overhead, payroll, taxes, and interest of 75.53M.
Check also Bharat Immunologicals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool. Please also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Search macroaxis.com